Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis

Journal of Neuroimmunology

Volumn 160, Issue 1-2, 2005, Pages 170-177

  Van Der Flier, M ^a,b   Coenjaerts, F E ^b   Mwinzi, P N ^b   Rijkers, E ^b   Ruyken, M ^b   Scharringa, J ^b   Kimpen, J L L ^a   Hoepelman, A I M ^b,c   Geelen, S P M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

(VEGF) Vascular endothelial growth factor; Bacterial meningitis; Brain edema; Vascular permeability

Indexed keywords

NEUTRALIZING ANTIBODY; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; BRAIN WATER; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; INOCULATION; LEUKOCYTE COUNT; NONHUMAN; PLEOCYTOSIS; PRIORITY JOURNAL; RABBIT; STREPTOCOCCUS PNEUMONIAE; WATER CONTENT;

EID: 13844269012     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.11.013     Document Type: Article

References (44)

1. B. Barleon, F. Totzke, C. Herzog, S. Blanke, E. Kremmer, and G. Siemeister Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1 J. Biol. Chem. 272 16 1997 10382 10388
2. D.H. Cherwek, M.B. Hopkins, M.J. Thompson, B.H. Annex, and D.A. Taylor Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia Am. J. Physiol. Heart Circ. Physiol. 279 3 2000 H932 H938
3. M. Cristofanilli, C. Charnsangavej, and G.N. Hortobagyi Angiogenesis modulation in cancer research: novel clinical approaches Nat. Rev., Drug Discov. 1 6 2002 415 426
4. M. Detmar, L.F. Brown, M.P. Schon, B.M. Elicker, P. Velasco, and L. Richard Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice J. Invest. Dermatol. 111 1 1998 1 6
5. B.P. Eliceiri, R. Paul, P.L. Schwartzberg, J.D. Hood, J. Leng, and D.A. Cheresh Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability Mol. Cell 4 6 1999 915 924
6. K.A.C. Elliott, and H. Jasper Measurement of experimentally induced brain swelling and shrinkage Am. J. Physiol. 157 1949 122 129
7. N.H. Fernando, and H.I. Hurwitz Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer Semin. Oncol. 30 3 Suppl. 6 2003 39 50
8. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 6 2003 669 676
9. H.P. Gerber, A.K. Malik, G.P. Solar, D. Sherman, X.H. Liang, and G. Meng VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism Nature 417 6892 2002 954 958
10. R. Gomez, C. Simon, J. Remohi, and A. Pellicer Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade Endocrinology 143 11 2002 4339 4348
11. M.S. Gordon, K. Margolin, M. Talpaz, G.W. Sledge Jr., E. Holmgren, and R. Benjamin Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J. Clin. Oncol. 19 3 2001 843 850
12. J.D. Heiss, E. Papavassiliou, M.J. Merrill, L. Nieman, J.J. Knightly, and S. Walbridge Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor J. Clin. Invest. 98 6 1996 1400 1408
13. H. Hurwitz, L. Fehrenbacher, T. Cartwright, J. Hainsworth, W. Heim, and J. Berlin Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluouracil, leucovorin) as first-line therapy in subjects with metastatic CRC The American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 3 2003, Chicago, IL 2003 Abstract 3646
14. K.L. Jin, X.O. Mao, and D.A. Greenberg Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia Proc. Natl. Acad. Sci. U. S. A. 97 18 2000 10242 10247
15. K. Jin, X.O. Mao, S.P. Batteur, E. McEachron, A. Leahy, and D.A. Greenberg Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor Neuroscience 108 2 2001 351 358
16. S. Kastenbauer, and H.W. Pfister Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases Brain 126 2003 1015 1025 (Pt. 5)
17. K.S. Kim Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury Nat. Rev., Neurosci. 4 5 2003 376 385
18. U. Koedel, W.M. Scheld, and H.W. Pfister Pathogenesis and pathophysiology of pneumococcal meningitis Lancet, Infect. Dis. 2 2002 721 736
19. B.C. Kuenen, M. Levi, J.C. Meijers, A.K. Kakkar, V.W. van Hinsbergh, and P.J. Kostense Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients Arterioscler. Thromb. Vasc. Biol. 22 9 2002 1500 1505
20. W. Leach, and G. Shopp Safety evaluation of bevacizumab in a rabbit dermal wound 1997 Report Genentech South San Francisco, C.A
21. F. Lechner, U. Sahrbacher, T. Suter, K. Frei, M. Brockhaus, and U. Koedel Antibodies to the junctional adhesion molecule cause disruption of endothelial cells and do not prevent leukocyte influx into the meninges after viral or bacterial infection J. Infect. Dis. 182 2000 978 982
22. T.H. Lee, H. Avraham, S.H. Lee, and S. Avraham Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells J. Biol. Chem. 277 12 2002 10445 10451
23. A. Luttun, K. Brusselmans, H. Fukao, M. Tjwa, S. Ueshima, and J.M. Herbert Loss of placental growth factor protects mice against vascular permeability in pathological conditions Biochem. Biophys. Res. Commun. 295 2 2002 428 434
24. Y. Moromizato, S. Stechschulte, K. Miyamoto, T. Murata, A. Tsujikawa, and A.M. Joussen CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury Am. J. Pathol. 157 4 2000 1277 1281
25. M.M. Mustafa, O. Ramilo, K.D. Olsen, P.S. Franklin, E.J. Hansen, and B. Beutler Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis J. Clin. Invest. 84 4 1989 1253 1259
26. S. Nag The blood-brain barrier and cerebral angiogenesis: lessons from the cold-injury model Trends Mol. Med. 8 1 2002 38 44
27. R. Nau, and W. Bruck Neuronal injury in bacterial meningitis: mechanisms and implications for therapy Trends Neurosci. 25 1 2002 38 45 (Jan.)
28. R. Paul, Z.G. Zhang, B.P. Eliceiri, Q. Jiang, A.D. Boccia, and R.L. Zhang Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke Nat. Med. 7 2 2001 222 227
29. H.W. Pfister, K. Frei, B. Ottnad, U. Koedel, A. Tomasz, and A. Fontana Transforming growth factor beta 2 inhibits cerebrovascular changes and brain edema formation in the tumor necrosis factor alpha-independent early phase of experimental pneumococcal meningitis J. Exp. Med. 176 1992 265 268
30. H.W. Pfister, W. Feiden, and K.M. Einhaupl Spectrum of complications during bacterial meningitis in adults. Results of a prospective clinical study Arch. Neurol. 50 1993 575 581
31. L.G. Presta, H. Chen, S.J. O'Connor, V. Chisholm, Y.G. Meng, and L. Krummen Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res. 57 20 1997 4593 4599
32. M.A. Proescholdt, J.D. Heiss, S. Walbridge, J. Muhlhauser, M.C. Capogrossi, and E.H. Oldfield Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain J. Neuropathol. Exp. Neurol. 58 6 1999 613 627
33. E. Rozdzinski, J. Sandros, M. van der Flier, A. Young, B. Spellerberg, and C. Bhattacharyya Inhibition of leukocyte-endothelial cell interactions and inflammation by peptides from a bacterial adhesin which mimic coagulation factor X J. Clin. Invest. 95 1995 1078 1085
34. S. Saadi, and J.L. Platt Transient perturbation of endothelial integrity induced by natural antibodies and complement J. Exp. Med. 181 1 1995 21 31
35. X. Saez-Llorens, and G.H. McCracken Jr. Bacterial meningitis in children Lancet 361 9375 2003 2139 2148
36. H.J. Schoch, S. Fischer, and H.H. Marti Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain Brain 125 Pt. 11 2002 2549 2557
37. J. Tureen, and E. Tuomanen Rabbit model of bacterial meningitis O. Zak M. Sande Handbook of animal models of infection 1999 Academic Press London 631 638
38. N. van Bruggen, H. Thibodeaux, J.T. Palmer, W.P. Lee, L. Fu, and B. Cairns VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain J. Clin. Invest. 104 11 1999 1613 1620
39. M. van der Flier, F. Coenjaerts, J.L. Kimpen, A.M. Hoepelman, and S.P. Geelen Streptococcus pneumoniae induces secretion of vascular endothelial growth factor by human neutrophils Infect. Immun. 68 2000 4792 4794
40. M. van der Flier, G. Stockhammer, G.J. Vonk, P.G. Nikkels, R.A. Diemen-Steenvoorde, and G.J. Der Vlist Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain J. Infect. Dis. 183 2001 149 153
41. M. van der Flier, S.P. Geelen, J.L. Kimpen, I.M. Hoepelman, and E.I. Tuomanen Reprogramming the host response in bacterial meningitis: how best to improve outcome? Clin. Microbiol. Rev. 16 3 2003 415 429
42. S.A. Vinores, Y. Wang, M.A. Vinores, N.L. Derevjanik, A. Shi, and D.A. Klein Blood-retinal barrier breakdown in experimental coronavirus retinopathy: association with viral antigen, inflammation, and VEGF in sensitive and resistant strains J. Neuroimmunol. 119 2 2001 175 182
43. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, and R.T. Tong Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2 2004 145 147
44. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, and S.L. Topalian A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 349 5 2003 427 434